XOMA Corporation (NASDAQ:XOMA) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Wednesday, July 12th.
Other equities analysts have also recently issued research reports about the company. Zacks Investment Research raised XOMA Corporation from a “sell” rating to a “hold” rating in a report on Thursday, March 23rd. HC Wainwright assumed coverage on XOMA Corporation in a report on Monday, June 12th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Wedbush reaffirmed a “neutral” rating and issued a $9.00 price target (down previously from $14.00) on shares of XOMA Corporation in a report on Monday, March 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. XOMA Corporation has an average rating of “Hold” and a consensus price target of $10.67.
XOMA Corporation (NASDAQ XOMA) traded up 2.46% on Wednesday, hitting $7.49. The stock had a trading volume of 90,518 shares. The stock’s market cap is $56.81 million. The stock’s 50 day moving average is $7.07 and its 200 day moving average is $6.19. XOMA Corporation has a one year low of $0.34 and a one year high of $8.13.
In other news, Director John Varian sold 39,540 shares of the company’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $6.24, for a total value of $246,729.60. Following the sale, the director now directly owns 2,344 shares in the company, valued at approximately $14,626.56. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 3.92% of the company’s stock.
A hedge fund recently bought a new stake in XOMA Corporation stock. Stonepine Capital Management LLC purchased a new position in XOMA Corporation (NASDAQ:XOMA) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 87,960 shares of the biotechnology company’s stock, valued at approximately $625,000. XOMA Corporation comprises 0.4% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 19th largest position. Stonepine Capital Management LLC owned approximately 1.17% of XOMA Corporation as of its most recent filing with the SEC. 31.34% of the stock is owned by hedge funds and other institutional investors.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with our FREE daily email newsletter.